New insight into a mysterious form of leukemia that can appear and then disappear in children with Down syndrome could have implications for other forms of leukemia and even other diseases.
Researchers have linked a mutation causing Down syndrome-associated leukemias to abnormalities in cells that produce platelets, called megakaryocytes.
Essentially, this mutation is interfering with an enzyme, Calpain 2, that acts as an initial trigger for a chain of reactions that determines size and shape of megakaryocytes. This interference causes the normal process of cellular enlargement and platelet production to get hung up.
“It’s like there’s a long pipeline and there’s a clog,” says Adam N. Goldfarb of the department of pathology at the University of Virginia. “We think it’s this pipeline that’s getting clogged in this disease and other diseases.”
As reported in the journal Developmental Cell, leukemia cells with the mutation display a critical deficiency of Calpain 2, and the enzyme’s absence leaves them stuck in an early stage of development, contributing to the development of Down syndrome-associated leukemias, Goldfarb says. And that could be the case in other forms of leukemia as well.
“These leukemias in Down syndrome aren’t that common, but this finding has implications for other leukemias in that it lets us understand basic growth and development patterns,” Goldfarb says.
Restoring Calpain 2 expression in affected cells fixed the problem and allowed the normal megakaryocyte developmental process to resume. As such, the researchers think that calpain deficiency could be a key defect in Down syndrome-associated leukemias, opening up a new target for developing more effective treatments.
And, eventually, it could lead to ways for doctors to mimic the natural process that allows a subset of Down syndrome-associated leukemias to disappear spontaneously.
The new research is also notable for the understanding it provides about the development and growth of megakaryocytes, the large cells that produce platelets. Megakaryocytes recover slowly after chemotherapy, and they’re easily destroyed, so it’s important to understand how they develop and find ways to control their replication and growth.
Megakaryocytes differ in size in neonatal infants versus older individuals, and they behave differently as well. By understanding why, scientists may one day be able to toggle them between the forms seen in neonates—when they’re smaller but proliferate more quickly—and in adults, when they’re more effective at platelet production. That could prove invaluable in developing new treatments for low platelet counts.
Researchers from Harvard and Queen’s University in Ontario contributed to the study.
Source: University of Virginia